5-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)picolinic acid | 1224449-36-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)picolinic acid
• 英文别名: 5-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]oxypyridine-2-carboxylic acid
• CAS: 1224449-36-8
• 化学式: C₁₆H₂₂N₂O₅
• 分子量: 322.361
• InChiKey: HMNRMGVTCJGTOX-UHFFFAOYSA-N

物化性质

• 沸点：
  480.9±45.0 °C(Predicted)
• 密度：
  1.240±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  89
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)picolinic acid 在 盐酸 、 sodium cyanoborohydride 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.17h， 生成 N-(4-(3-(5-tert-butylisoxazol-3-yl)ureido)phenyl)-5-(1-ethylpiperidin-4-yloxy)picolinamide
  参考文献：
  名称：

  Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases

  摘要：

  A series of potent, selective platelet-derived growth factor receptor-family kinase inhibitors was optimized starting from a globally selective lead molecule 4 through structural modifications aimed at improving the physiochemical and pharmacoldnetic properties, as exemplified by 18b. Further clearance reduction via per-methylation of the a-carbons of a solubilizing piperidine nitrogen resulted in advanced leads 22a and 22b. Results from a mouse tumor xenograft, a collagen-induced arthritis model, and a 7 day rat in vivo tolerability study culminated in the selection of compound 22b (AC710) as a preclinical development candidate.

  DOI：

  10.1021/ml300214g
• 作为产物：
  描述：

  2-氰基-5-氟吡啶 在 水 、 sodium hydride 、 sodium hydroxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 1.5h， 生成 5-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)picolinic acid
  参考文献：
  名称：

  Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases

  摘要：

  A series of potent, selective platelet-derived growth factor receptor-family kinase inhibitors was optimized starting from a globally selective lead molecule 4 through structural modifications aimed at improving the physiochemical and pharmacoldnetic properties, as exemplified by 18b. Further clearance reduction via per-methylation of the a-carbons of a solubilizing piperidine nitrogen resulted in advanced leads 22a and 22b. Results from a mouse tumor xenograft, a collagen-induced arthritis model, and a 7 day rat in vivo tolerability study culminated in the selection of compound 22b (AC710) as a preclinical development candidate.

  DOI：

  10.1021/ml300214g

文献信息

• [EN] COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE TRADUCTION DU COLLAGÈNE 1 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ANIMA BIOTECH INC

  公开号：WO2021252555A1

  公开（公告）日：2021-12-16

  The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).

  本发明涉及新型胶原蛋白1翻译抑制剂，其组成物及其制备方法，以及用于治疗包括肺部、肝脏、肾脏、心脏和皮肤纤维化、IPF、伤口愈合、瘢痕和牙龈纤维瘤病、全身性硬皮病，以及酒精性和非酒精性脂肪肝（NASH）的用途。
• [EN] AZOLYL UREA COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS AZOLYLE URÉE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：AMBIT BIOSCIENCES CORP

  公开号：WO2011150198A1

  公开（公告）日：2011-12-01

  Provided herein are azolyl urea compounds for treatment of CSF-1R kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

  本文提供了用于治疗CSF-1R激酶介导疾病的唑啉基脲化合物。还提供了包含这些化合物的药物组合物以及使用这些化合物和组合物的方法。
• Azolyl Urea Compounds and Methods of Use Thereof
  申请人：Liu Gang

  公开号：US20130310357A1

  公开（公告）日：2013-11-21

  Provided herein are azolyl urea compounds for treatment of CSF-1R kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

  本文提供了用于治疗CSF-1R激酶介导疾病的氮杂基脲化合物。还提供了包含这些化合物的药物组合物以及使用这些化合物和组合物的方法。
• US9296722B2
  申请人：——

  公开号：US9296722B2

  公开（公告）日：2016-03-29
• [EN] HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE<br/>[FR] MODULATEURS HÉTÉROCYCLIQUES DE GPR119 POUR LE TRAITEMENT D'UNE MALADIE
  申请人：KALYPSYS INC

  公开号：WO2010048149A2

  公开（公告）日：2010-04-29

  Disclosed herein are compounds and methods which may be useful as inhibitors of GPR 119 for the treatment or prevention of diseases including cardiovascular and metabolic diseases.